Joseph Schwartz
Stock Analyst at Leerink Partners
(4.10)
# 536
Out of 5,113 analysts
160
Total ratings
35.04%
Success rate
21.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $80 → $70 | $24.44 | +186.42% | 7 | Dec 30, 2025 | |
| FOLD Amicus Therapeutics | Downgrades: Market Perform | $17 → $15 | $14.28 | +1.54% | 13 | Dec 29, 2025 | |
| APLT Applied Therapeutics | Downgrades: Market Perform | $2 → $1 | $0.09 | +971.81% | 3 | Dec 3, 2025 | |
| SPRB Spruce Biosciences | Upgrades: Outperform | $160 | $81.90 | +95.36% | 7 | Dec 3, 2025 | |
| DSGN Design Therapeutics | Upgrades: Outperform | $7 → $14 | $10.13 | +38.20% | 5 | Dec 3, 2025 | |
| IFRX InflaRx | Downgrades: Market Perform | $5 → $2 | $0.91 | +119.56% | 5 | Dec 3, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | $82 → $60 | $56.68 | +5.86% | 11 | Dec 3, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Market Perform | $15 → $16 | $14.57 | +9.81% | 7 | Dec 3, 2025 | |
| QURE uniQure | Maintains: Outperform | $68 → $60 | $23.02 | +160.64% | 3 | Nov 10, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Outperform | $115 | $67.44 | +70.53% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $65 → $72 | $72.46 | -0.63% | 4 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $88 | $51.32 | +71.47% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $12 → $15 | $21.31 | -29.61% | 14 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $15.14 | +32.10% | 6 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $115 | $155.89 | -26.23% | 4 | Jun 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $12 | $10.48 | +14.50% | 4 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $43.36 | -35.42% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $40 | $30.28 | +32.10% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.19 | - | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $6.55 | +83.21% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $0.45 | +1,681.74% | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $75.60 | -36.51% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $27.86 | -35.39% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $81.92 | -58.50% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $222.45 | -26.73% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.55 | +292.16% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $5.22 | +532.18% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $64 → $52 | $10.34 | +402.90% | 5 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $28.68 | +4.60% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $81.76 | -63.31% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $1.62 | +640.74% | 2 | Sep 26, 2017 |
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Outperform
Price Target: $80 → $70
Current: $24.44
Upside: +186.42%
Amicus Therapeutics
Dec 29, 2025
Downgrades: Market Perform
Price Target: $17 → $15
Current: $14.28
Upside: +1.54%
Applied Therapeutics
Dec 3, 2025
Downgrades: Market Perform
Price Target: $2 → $1
Current: $0.09
Upside: +971.81%
Spruce Biosciences
Dec 3, 2025
Upgrades: Outperform
Price Target: $160
Current: $81.90
Upside: +95.36%
Design Therapeutics
Dec 3, 2025
Upgrades: Outperform
Price Target: $7 → $14
Current: $10.13
Upside: +38.20%
InflaRx
Dec 3, 2025
Downgrades: Market Perform
Price Target: $5 → $2
Current: $0.91
Upside: +119.56%
BioMarin Pharmaceutical
Dec 3, 2025
Downgrades: Market Perform
Price Target: $82 → $60
Current: $56.68
Upside: +5.86%
Aurinia Pharmaceuticals
Dec 3, 2025
Downgrades: Market Perform
Price Target: $15 → $16
Current: $14.57
Upside: +9.81%
uniQure
Nov 10, 2025
Maintains: Outperform
Price Target: $68 → $60
Current: $23.02
Upside: +160.64%
Monopar Therapeutics
Nov 10, 2025
Initiates: Outperform
Price Target: $115
Current: $67.44
Upside: +70.53%
Oct 27, 2025
Downgrades: Market Perform
Price Target: $65 → $72
Current: $72.46
Upside: -0.63%
Sep 29, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $51.32
Upside: +71.47%
Sep 9, 2025
Maintains: Market Perform
Price Target: $12 → $15
Current: $21.31
Upside: -29.61%
Jul 7, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $15.14
Upside: +32.10%
Jun 10, 2025
Maintains: Outperform
Price Target: $100 → $115
Current: $155.89
Upside: -26.23%
May 23, 2025
Upgrades: Outperform
Price Target: $4 → $12
Current: $10.48
Upside: +14.50%
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $43.36
Upside: -35.42%
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $30.28
Upside: +32.10%
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.19
Upside: -
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $6.55
Upside: +83.21%
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $0.45
Upside: +1,681.74%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $75.60
Upside: -36.51%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $27.86
Upside: -35.39%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $81.92
Upside: -58.50%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $222.45
Upside: -26.73%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.55
Upside: +292.16%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $5.22
Upside: +532.18%
Aug 5, 2022
Downgrades: Market Perform
Price Target: $64 → $52
Current: $10.34
Upside: +402.90%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $28.68
Upside: +4.60%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $81.76
Upside: -63.31%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $1.62
Upside: +640.74%